Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 663 across all filing types
Latest filing 2026-05-18 Capital/Financing Update
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 95% confidence The document is a press release dated May 18, 2026, announcing the signing of a term-sheet for a collaboration and exclusive license agreement between Valerio Therapeutics and another biotechnology company. It details the potential financial terms (up to $200 million and royalties) and strategic significance of the collaboration. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is an announcement of a capital-related transaction (a term-sheet for collaboration and licensing with financial implications) rather than a full financing report or earnings release. It fits best under Capital/Financing Update (CAP) as it provides an update on a financing-related agreement and potential future payments. The document length (5817 characters) and content confirm it is not a mere announcement of a report publication or a regulatory filing. Therefore, the classification is CAP with high confidence.
2026-05-18 French
Inside Information / Other news releases
Capital/Financing Update Classification · 95% confidence The document is a press release dated May 18, 2026, announcing a binding term-sheet for a collaboration and exclusive license agreement between Valerio Therapeutics and a seed-stage biotech company. It details the terms of the collaboration, potential milestone payments, and royalties. The document is focused on a financing and partnership update rather than financial results, regulatory filings, or management changes. It does not contain financial statements or detailed financial analysis, nor is it a report or transcript. The content aligns with an update on company fundraising or capital structure changes through a collaboration agreement. Therefore, the document fits best under Capital/Financing Update (CAP). The document length is 5207 characters, sufficient for a detailed announcement but not a full report. Confidence is high given the clear focus on a financing-related collaboration announcement.
2026-05-18 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated May 4, 2026, announcing the launch of a new company, InVimmune, by Valerio Therapeutics. It describes the strategic rationale, scientific advisory board, and management appointments related to this new venture. There is no financial data, no regulatory filing references, no voting results, no earnings information, and no detailed financial or management report content. The document is a corporate announcement about a new business initiative and organizational changes but does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a report publication announcement since it does not mention the release or availability of a report. The best fitting category is Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2026-05-04 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new company, InVimmune, by Valerio Therapeutics. It focuses on strategic business development, scientific advisory board appointments, and future plans for the new company. There is no financial data, regulatory filing references, voting results, or detailed financial performance information. The document is a corporate announcement about a new business initiative rather than a financial report, regulatory filing, or shareholder meeting material. Therefore, it fits best under the category of a general regulatory announcement or corporate news update, which corresponds to Regulatory Filings (RNS).
2026-05-04 English
Annual financial and audit reports / Terms of availability of the annual financial report
Earnings Release Classification · 85% confidence The document is a press release announcing Valerio Therapeutics’ 2025 annual results and summarizing key financial metrics (revenues, operating expenses, cash position) and strategic highlights. It does not contain the full annual report itself but provides an initial announcement of periodic financial results and refers readers to the full report on the company website. This matches the definition of an Earnings Release (ER) rather than an actual Annual Report (10-K) or a brief Report Publication Announcement (RPA). FY 2025
2026-04-29 English
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Earnings Release Classification · 85% confidence The document is a press release (“COMMUNIQUÉ DE PRESSE”) presenting Valerio Therapeutics’ annual 2025 results, key financial highlights (revenues, operating expenses, cash), strategic update and outlook. It summarizes performance and confirms the availability of the full annual report on the company’s website, without containing the full financial statements themselves. This aligns with an Earnings Release (initial announcement of periodical results), not the full Annual Report (10-K) nor merely a publication notice. Thus, it should be classified as an ER. FY 2025
2026-04-29 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.